NEJM February 19 2026 Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

This clinical study evaluates the effectiveness of combining two targeted immunotherapies, teclistamab and daratumumab, to treat patients with multiple myeloma who have failed previous therapies. By utilizing a bispecific antibody alongside a monoclonal antibody, this dual approach aims to bridge immune cells directly to cancer cells for more efficient destruction. The research demonstrates that this novel combination significantly improves progression-free survival and achieves higher rates of complete remission compared to standard treatment regimens. While the combination therapy offers a powerful new strategy for controlling the disease, it also carries a slightly higher risk of serious adverse events that must be carefully managed.